In-vivo Electrophysiological Study of Induced Ventricular Tachycardia in Intact Rat Model of Chronic Ischemic Heart Failure

Kyle Weigand1,3, Russell Witte1,3, Talal Moukabary4, Ike Chinyere1,2, Jordan Lancaster1,2, Mary Kaye Pierce5, Steven Goldman1,5, Elizabeth Juneman1,5

Abstract—Objective: The objective of this study was to define the clinical relevance of in-vivo electrophysiological (EP) studies in a rat model of chronic ischemic heart failure (CHF). Methods: Electrical activation sequences, voltage amplitudes, and monophasic action potentials (MAPs) were recorded from adult male Sprague-Dawley rats six weeks after left coronary artery ligation. Programmed electrical stimulation (PES) sequences were developed to induce sustained ventricular tachycardia (VT). The inducibility of sustained VT was defined by PES and the recorded tissue monophasic action potentials. Results: Rats in CHF were defined (p<0.05) by elevated left ventricular (LV) end-diastolic pressure (5±1 vs 18±2 mmHg), decreased LV +dP/dt (7496±225 vs 5502±293 mmHg/sec), LV -dP/dt (7723±208 vs 3819±571 mmHg), LV ejection fraction (79±3 vs 30±3%), peak developed pressure (176±4 vs 145±9 mmHg), and prolonged time constant of LV relaxation tau (18±1 vs 29±2 ms). The EP data showed decreased (p<0.05) electrogram amplitude in border and infarct zones (Healthy zone (H): 8.7±2.1 mV, Border zone (B): 5.3±1.6 mV, Infarct zone (I): 2.3±1.2 mV), decreased MAP amplitude in the border zone (H: 14.0±1.0 mV, B: 9.7±0.5 mV), and increased repolarization heterogeneity in the border zone (H: 8.1±1.5 ms, B: 20.2±3.1 ms). With PES we induced sustained VT (>15 consecutive PVCs) in rats with CHF (10/14) vs. Sham (0/8). Conclusions: These EP studies establish a clinically-relevant protocol for studying genesis of VT in CHF. Significance: The in-vivo rat model of CHF combined with EP analysis could be used to determine the arrhythmogenic potential of new treatments for CHF.

Index Terms—Activation mapping, Arrhythmias, Chronic heart failure (CHF), Electrophysiology (EP), Ischemia,

Monophasic action potential (MAP), Myocardial infarction (MI), Rat model CHF, Ventricular tachycardia (VT)

I. INTRODUCTION

Ventricular tachycardia (VT) and ventricular fibrillation (VF) are the most common causes of sudden cardiac death in patients with chronic heart failure (CHF). As the next generation of therapeutics for heart failure is developed, it is increasingly important to have reliable and clinically relevant pre-clinical models for characterizing the effects of drugs/treatments in the presence of myocardial infarction (MI) and CHF [1]-[3]. Furthermore, the complex and variable mechanisms of arrhythmias make predicting the electrical effects of new treatments in isolated cell preparations or perfused hearts difficult. For example, initial in-vitro studies found cell transplantation to increase the likelihood of arrhythmias, while recent in-vivo studies suggest the opposite [4]. In-vivo animal models that allow for electrophysiological (EP) characterization of the effects of drugs, biologics, stem cells, and devices could define risk prior to the use in patients. In order to precisely define these changes, models for testing new therapies must be robust and clinically relevant in the realm of EP characterization. Tissue electrograms (for EP mapping) and monophasic action potential (MAP) recordings can help define the electrical integration of new treatments and potential associated arrhythmia risk [4]-[7]. To address this, we developed clinically-relevant methods including EP mapping, MAP recording, and arrhythmia induction by programmed electrical stimulation (PES), permitting in-vivo EP evaluation in an intact rat model of CHF.

Coronary artery ligation rat models of MI and CHF are also good models of ischemic cardiomyopathy that accurately predict clinical responses to drugs now used as standard therapy for CHF, such as angiotensin converting enzyme inhibitors and angiotensin receptor blockers [8], [9]. These studies accurately predicted the effects of these drugs on patients with CHF, not only in terms of improved left ventricular (LV) function, but also improved survival. These drugs are now the first line treatment for patients with heart failure. Therefore, understanding and performing EP testing in this model may be valuable in pre-clinical translational research. In this study, we describe the same coronary artery ligation rat model of CHF with full EP characterization in the in-vivo rat heart, including epicardial and MAP recording of healthy and infarcted tissue, as well as PES-induced arrhythmia with simultaneous MAP and electrocardiogram.
(ECG) recording. The methods generate EP datasets similar to what is observed in patients, including voltage amplitude decrease and conduction delay in infarcted tissue. Furthermore, MAP data allow for spatial localization of EP properties (such as repolarization heterogeneity) with respect to the underlying distribution of ischemic myocardium. We investigate these changes as they relate to the inducibility of arrhythmias in this model, and find that increased arrhythmia risk correlates strongly with viable myocardium which has an abnormal action potential duration (APD), thus indicating a physiological substrate for re-entry. Finally, MAP is recorded in the infarct border zone during the induction of ventricular tachycardia, providing additional insight regarding mechanisms of arrhythmia and evolution of tissue in the region surrounding the scar.

II. METHODS

A. Coronary Artery Ligation—CHF Induction

Rats in this study received humane care in compliance with IACUC-approved protocols at the University of Arizona. The rat coronary artery ligation technique is commonly used in our laboratory and is a well-established model to study the pathophysiology of CHF [2], [9]-[12]. In brief, male Sprague-Dawley rats were anesthetized with ketamine mixture and underwent a left thoracotomy. The heart was expressed from the thorax and a ligature placed around the proximal left coronary artery. Rats were recovered for 6 weeks to develop CHF.

B. Echocardiography

Transthoracic echocardiography was performed using a Vevo® 2100 (Visual Sonics, ON, Canada) rodent echocardiography system and 25 MHz probe at 6 weeks post-MI with views in the parasternal short axis and long axis, to evaluate the anterior, lateral, antero-lateral, inferior and posterior walls. Systolic displacement of the anterior wall and ejection fraction (EF) were obtained from 2D and M-mode measurements of myocardial wall thickness and LV dimensions [10]-[12]. Rats with EF ≤50% following permanent left coronary artery ligation at 3 weeks post-MI were enrolled in the study.

C. In-vivo Hemodynamic Measurements

Rats were anesthetized with an injection of Inactin (Sigma-Aldrich, St. Louis, MO), intubated, placed on a rodent ventilator and heated platform. A 3F pressure catheter (AD Instruments, Colorado Springs, CO) was inserted through the carotid artery. The pressure sensor was equilibrated in 37 ºC.

D. Electrophysiological Mapping

Unipolar and bipolar recordings were obtained from multiple locations spanning the infarcted LV and surrounding tissue by a 4-electrode EP catheter (Biosense Webster, Diamond Bar, CA). The two recording electrodes were used to map the epicardial surface of the ventricles and the resultant electrograms were used to generate voltage and activation maps (Fig. 2). Pacing was performed at 2X diastolic threshold. All waveforms were collected at a sampling rate of 2 kHz using a Biopac biosignal amplifier MP150 and MCE100C modules (Biopac Systems, Goleta, CA) and custom MATLAB software. Unipolar waveforms were high-pass filtered at 0.05 Hz and low-pass filtered at 100 Hz, and bipolar waveforms were high-pass filtered at 2.5 Hz and low-pass filtered at 500 Hz. All signals were notch filtered at 60 Hz to reduce contamination from electrical mains. Custom software developed in MATLAB analyzed waveforms for peak (absolute) voltage to define local voltage amplitude, and time to max |dV/dt| from reference electrode in the right ventricle (RV), to define local activation time. Voltage and activation values were visualized using clinically-relevant color maps and interpolated in 2-D to visualize ischemic tissue distribution and activation sequence. The thresholds were determined by a trained electrophysiologist (TM), who analyzed voltage mapping data and tissue gross appearance. We had to determine appropriate thresholds in rats with myocardial infarctions and CHF, since this has not been reported previously in rats with epicardial recording. For reference and orientation, the maps were then overlaid on images of the heart in accordance with anatomical landmarks including the septum and the visible scar border (Fig. 2). The surface ECG is used as a common point of reference. Since the electrograms are fractioned, the activation time is determined similar to the way it is done clinically in fractionated tissue. It is reviewed personally by the operator and compared to the surrounding tissue to choose the appropriate peak. If no clear local activation time was the
E. Monophasic Action Potential Recording

Monophasic action potentials were recorded using a concentric bipolar electrode (World Precision Instruments, Sarasota, FL) at a sampling rate of 2 kHz using a Biopac biosignal amplifier and custom MATLAB software. The electrode was held in place with slight pressure applied to the LV epicardium. The electrode was not fixed or sutured; however, the pressure on the electrode ensured proper positioning during the beating of the heart. A motion artifact was occasionally observed resulting in unstable baseline, and these recordings were excluded from analysis. MAP recordings were obtained from multiple locations in healthy tissue and border tissue zones. Border tissue zone was identified visually and verified with associated voltage maps. A minimum of three recordings with stable baseline and consistent beat-to-beat morphology were chosen from each zone for subsequent analysis performed in MATLAB. Feature extraction included identification of MAP upstroke defined by max dV/dt, baseline, amplitude, and duration at 50, 75, and 90% repolarization. Repolarization heterogeneity was defined as the largest difference between measured MAPD90 between locations within each zone, as previously defined in other studies [13].

F. Ventricular Tachycardia Induction

A protocol for PES was developed for studies in rats in accordance with the Lambeth conventions and using a modified version of the MUSTT Protocol for our studies [3], [4], [15]. Rats were paced from a healthy tissue in the RV at twice diastolic threshold for a drive-train of 8 beats at a cycle length of S1-S1 = 160 ms, followed by up to two extra stimuli (S2, S3). S1-S2 and S2-S3 coupling intervals were decreased by 5 ms on each attempt until loss of capture. The effective refractory period (ERP) was defined as the longest S1-S2 interval with unsuccessful capture on S2. The second extra stimulus (S3) was not added until all S2’s leading up to the ERP were delivered. The procedure ended when: i) all pacing waveforms had been attempted through S3 loss of capture or ii) the animal exhibited long sustained VT resulting in compromised heart function. The MAP electrode was held in place at a location in the infarct border zone to record action potential changes during the induction of VT to capture localized EP data in addition to the surface ECG. Action potential recordings can help researchers distinguish between re-entrant mechanisms and abnormal impulse formation via the observation of after-depolarizations. VT inducibility was summarized by the fraction of animals that exhibited induced sustained VT defined by VT lasting longer than 15 beats [16]-[20].

The activation sequence of VT was not mapped because we did not have the ability to record from multiple locations along the epicardial surface simultaneously. Our EP mapping was accomplished through a “stitched” mapping technique with waveforms collected at each site individually. In order to appropriately map VT, the VT needs to be sustained, monomorphic VT and last long enough to achieve the constituent recordings. In this model, even the longest VT events would not have allowed for this, given the limitations of our current technique.
G. Statistical Analysis

Data are expressed as mean±SEM. Student’s t-test for independent population means was used in analyzing significant changes (p<0.05) with CHF (Table I). Paired t-test was used for comparing MAP measurements taken from healthy and border tissue zones within the CHF group, and unpaired t-test was used for comparing MAP measurements between sham and CHF groups.

III. RESULTS

A. Left Ventricular Function

Hemodynamic parameters representative of LV function are presented in Table I for Sham (N=8) and CHF (N=14) rats. Significant changes (p<0.05) in the CHF included the following (Table I): elevated LV end-diastolic pressure, decreased +LV dP/dt, decreased -LV dP/dt, decreased LV Ejection Fraction, decreased peak developed pressure, and prolonged time constant of LV relaxation/tau. These data are consistent with previous work in our laboratory documenting that this is a model of CHF [9]-[12].

B. Electrophysiological Mapping

Unipolar electrogram amplitudes decreased in the border zone and further decreased in the infarct zone (Healthy tissue zone (H): 8.7±2.1 mV, Border zone (B): 5.3±1.6 mV, Infarct zone (I): 2.3±1.2 mV, see Fig. 2c). Bipolar recordings taken from ischemic tissue exhibited increased fractionation, which occasionally made it difficult to determine activation time. Therefore, all waveforms were visually inspected to verify the deflection representative of local activation. The maps generated correlated well with visual observation of myocardial scar distribution with regard to both amplitude and activation time, and delayed activation through scar was consistently observed.

C. MAP Recording

Monophasic action potential recordings showed expected morphology in healthy tissue (H) and in the border zone (B). Recordings taken from dense scar more closely resembled bipolar electrograms and were not used for analysis. MAP recordings in post-MI animals displayed a significant (p<0.05) reduction in amplitude in the border zone (H: 14.0±1.0 mV, B: 9.7±0.5 mV), increased repolarization heterogeneity in the border zone (H: 8.1±1.5 ms, B: 20.2±3.1 ms), and decreased upstroke velocity (H: 0.88±0.06 V/s, B: 0.65±0.05 V/s) (Fig. 2). Sample MAP recordings during sinus rhythm from each tissue zone are presented in Fig. 3.

D. VT Induction with Programmed Electrical Stimulation

Fourteen CHF rats and eight sham rats underwent PES for VT induction. Zero (out of 8) sham rats exhibited sustained VT (as defined as >15 consecutive beats), while ten of the fourteen (71.4%) CHF rats exhibited sustained VT (Fig. 4). Two sham rats exhibited brief episodes of non-sustained VT. MAP recording during the induction of VT enabled capture of local activity for studying mechanisms of different arrhythmia. This not only includes the classic re-entry but also triggered activity that was initiated by pacing. Triggered activity could explain the premature ventricular contractions and triggered ventricular tachycardia that is occasionally observed clinically.

Fig 3. Summary of analysis for MAP recordings. a) In CHF animals, border and healthy tissue zones were defined visually and verified using EP maps. In sham animals, border zone was defined by analogous locations on the LV, labelled as anterior LV (ALV) for sham healthy and mid LV (MLV) for sham border. Example waveforms from each tissue type shown below CHF heart; anterior LV (ALV) for sham healthy, mid LV (MLV) for sham border. MAP recordings taken from dense scar more closely resembled bipolar electrograms and were not used for analysis. MAP recordings from analysis. b) Table of values for MAP waveform analysis. Repolarization heterogeneity defined for each animal as the difference between the longest and the shortest measured 90% monophasic action potential duration (MAPD90) in each zone. As expected, there is no change between healthy (ALV) and border (MLV) zone for sham animals. In CHF animals, amplitude of MAP decreases, repolarization heterogeneity increases, MAPD90 and MAPD50 increase, and upstroke velocity decreases in the border zone.
IV. DISCUSSION

The goals of this study were to develop methods to i) define and implement the induction of VT in rat coronary artery ligation model of ischemic CHF, and to ii) characterize EP changes at the tissue level using clinically relevant techniques in-vivo. It is important to stress the clinical relevance of this model of CHF; first and foremost, we are studying an intact animal and not an isolated cell or perfused heart preparation. This is a model of stable CHF, as opposed to studying acute MI, where the genesis of ventricular arrhythmias is acute myocardial ischemia and the treatment is direct current cardioversion or institution of drug therapy such as lidocaine or amiodarone. In acute MI, the presence of ventricular arrhythmias does not predict mortality as closely as it does in CHF. In this model of CHF, ventricular remodeling has already taken place, with scar formation thus setting up the milieu for VT/VF that clearly predicts mortality. In this report, we define functional changes with hemodynamics and echocardiography documenting the presence of CHF in the rat in-vivo, in addition to electrophysiological changes with EP mapping and MAP recordings, and risk of ventricular arrhythmia based on VT inducibility with PES. These data reflect what is seen clinically in CHF, suggesting that this model is a good representation of the pathophysiology of CHF.

To further clarify and compare our data to clinical data, VT in patients is defined as a ventricular rate of greater than 100 beats/min and sustained VT is defined as lasting a minimum length of 30 seconds. Therefore, 30 seconds of VT at 100 beats/min would lead to a minimum of 50 consecutive ventricular beats for sustained VT in patients. In Figure 3, the VT rate is approximately 840 beats/min. To achieve 50 consecutive ventricular contractions, the clinical minimum, 4 seconds would suffice, so we and other investigators chose 15 beats, this clearly exceeds the threshold for defining sustained VT in patients [16]-[20].

A. Electrophysiological Mapping

Color maps for voltage amplitude and activation sequence were defined using clinically-relevant color schemes and reflect the obtained values for healthy and scar tissue from the epicardium. Threshold voltage for healthy tissue (8.1 mV) was defined such that 90% of measurements taken from healthy epicardium were above the threshold, and similarly the value for dense scar (4.2 mV) was defined such that 40% of measurements taken from the left ventricles (LV) of infarcted rats were below threshold. This allowed partially ischemic tissues to be distinguished from dense scar, and helped in defining border tissues while still visualizing the bulk of scar as a single color. The approach helps define threshold values for different tissue types in this model, producing color maps similar to what are used in the clinic to describe the distribution of ischemic tissue. To our knowledge, this is the first study to define epicardial voltage thresholds for healthy and ischemic cardiac tissue in the infarcted rat. The relatively large potentials from the epicardial surface of the rat may be due to the higher current densities in the thin wall of the rat heart compared to the human heart and has been observed by other groups.

B. Monophasic Action Potential

Monophasic action potential recordings have been used to examine the electrophysiology of healthy and ischemic myocardial tissues. The MAP signals from dense myocardial scar in small animals do not display an expected morphology, and this is consistent with what was observed in this study.
Therefore, it is assumed that MAP data can only compare healthy and partially ischemic tissues, as defined by EP maps and visual identification of tissue zones. We did not find a significant difference in overall APD between border zone (B) and healthy tissue (H) measurements (H: 61.7±2.6 ms, B: 65.3±2.8 ms). However, we did find a significant increase in repolarization heterogeneity between the two tissue types (H: 8.1±1.5 ms, B: 20.2±3.1 ms, P<0.007). This APD heterogeneity specific to the border zone could be indicative of an additional arrhythmic electrophysiological substrate [13], [14], and agrees with the increased inducibility of ventricular tachycardia in CHF animals. Recording action potentials prior to and during the induction of VT may provide additional information not detectable by the surface ECG. Analysis of these localized waveforms could help investigators distinguish the pathophysiology of the arrhythmia, and could therefore help explain changes in morphology based on known drug and arrhythmia mechanisms [21].

This information could help determine not only the effect of new agents on inducibility, but can help localize changes at the tissue level that contribute to formation of an arrhythmic substrate. This has important implications in testing new treatments for CHF in pre-clinical models before agents are tested in humans. In this study, we report examples of MAP recording during onset of different arrhythmias to illustrate the potential value and relevance of the technique for describing delayed afterdepolarizations (DAD) (Fig. 5), which are a consequence of the transient inward current that is related to abnormal calcium concentrations and/or handling. Delayed afterdepolarizations are pro-arrhythmic because they can lead to rapid depolarization of surrounding tissue promoting reentry. The finding of DADs is being proposed to suggest proarrhythmic potential of drugs using organ on a chip technology [22].

C. Potential future uses of this model

In addition to studying the effects of novel candidate drugs for treatment of CHF, this model could also be valuable for testing regenerative therapies for CHF. Previous studies described transplanted skeletal myoblasts resulted in VT in patients with CHF [23] and this work stimulated attempts at antiarrhythmic engineering of skeletal myoblasts [24]. Investigators are also assessing arrhythmogenic risk of myocardial cell transplantation and mesenchymal stem cells in isolated Langendorff preparations. There is clearly a need to better understand the genesis and evolution of ventricular arrhythmias in intact animal models. For example, we have a particular interest in using induced pluripotent stem cells to treat CHF in patients in which there are very limited data [14], [25]-[29].

This study employed a novel platform with analysis software to study arrhythmias in rats with CHF. A clinical EP catheter was combined with a graphical user interface (GUI) to perform EP studies in rats in-vivo. The software was customized to accommodate the fast intrinsic heart rate in rats and, consequently, shorter stimulus drive trains (S₁, S₂, S₃) compared to humans. The program can be easily modified to accommodate small or large animal models, as well as different heart rates and pacing thresholds. Finally, in the future, a feedback algorithm could be employed to automatically determine the optimal parameters and threshold for inducing VT. A hybrid electrode array capable of stimulation and multichannel recording would facilitate closed-loop feedback for inducing and mapping arrhythmias.

D. Study Limitations

In humans, the size of post-ischemic scar is bigger on the endocardial surface. While we performed epicardial mapping, the thickness of the ventricular wall is much less in the rat, so the trans-mural differences may be less. Although we defined the threshold voltage for healthy tissue as 8.1 mV and dense scar as 4.2mV, there is no current standard in the rat for determining these cut-off thresholds, so our empirical method may be useful for other in-vivo EP studies in rats for quantifying scar tissue. Because calcium handling in the rat heart is different than in humans, the genesis of arrhythmias may not perfectly predict this behavior in humans. Nonetheless, isolated perfused rat hearts have been used for many years to study the genesis of ventricular arrhythmias [30]-[32]. It is also possible to perform PES in intact rodents with a catheter introduced into the right ventricle [33]. While these reports show that ex-vivo rodent models can be used to study ventricular arrhythmias, we could not find reports using PES to induce sustained VT or MAPs to record arrhythmias in an intact rat model of ischemic CHF.

V. CONCLUSION

There is currently no effective clinical method to determine if a drug has the potential to induce VT in an animal model before it is tested on patients. We have presented EP studies with VT induction in an intact ischemic CHF rat model using modified clinical catheters and electrodes. The method we describe is a physiologic model where the electrical impulses can be characterized as they spread across native myocardium and predict the inducibility of sustained VT. The rat model and protocol could help determine the risk of arrhythmia from a new drug or treatment and offers an alternative to perfused rodent heart preparations or costly large animal models commonly used for this purpose.

VI. ACKNOWLEDGMENTS

We thank Maribeth Stansifer BS, Yexian Qin BA, Sherry Daughtery BS and Nicole LaHood, MD for their technical assistance.

REFERENCES


